UCLA brain cancer researchers reported two contrasting glioblastoma findings on October 13, 2026. A 63-patient study showed greater immune activity with two checkpoint drugs, while a mouse model reproduced resistance seen in human tumors. Together, the findings provide new information about immunotherapy responses without establishing a definitive survival benefit.
Key Takeaways
- Researchers randomized 63 patients with recurrent glioblastoma, and 58 received trial medication
- Combined nivolumab and ipilimumab increased immune-cell density in tumor tissue compared with presurgical placebo
- Median survival was 402 days in pooled dual-treatment groups versus 273 days with nivolumab alone, a secondary outcome
- A genetically engineered mouse model reproduced several features associated with glioblastoma treatment resistance
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center reported findings that distinguish immune activation from demonstrated treatment benefit in glioblastoma. The aggressive brain cancer frequently returns after surgery, radiation and chemotherapy, and immune checkpoint inhibitors have shown limited effectiveness against the disease.
The studies, published in Nature Communications and Cancer Research, examined the problem from different directions. One measured immune responses in patients receiving checkpoint inhibitors, while the other investigated biological conditions that may prevent those treatments from working.
UCLA Brain Cancer Trial Finds More T Cells After Two Drugs
In the phase 2 surgical-window trial, researchers screened 71 patients between 2021 and 2024. They randomized 63 participants with recurrent, surgically removable glioblastoma, and 58 received trial medication.
Before surgery, participants received nivolumab combined with ipilimumab, nivolumab alone or placebo. The two medications target different immune checkpoints that regulate T-cell activity. Researchers examined removed tumor tissue to determine how the treatments affected the immune response.
The surgical design allowed investigators to analyze tumors following drug exposure. It also placed biological samples used in research at the center of the trial’s primary measurement, enabling researchers to examine immune-cell density directly within tumor tissue.
Patients receiving both drugs before surgery showed significantly greater tumor-infiltrating lymphocyte density than those receiving presurgical placebo. These immune cells include T cells capable of recognizing abnormal cells, although their presence does not automatically establish that cancer growth has been controlled.
The combination also produced increased interferon-related immune signaling, suggesting that the treatment altered immune activity inside tumors and elsewhere in the body.
“This study shows that we can activate the immune system against glioblastoma in ways we have not previously seen,” said Timothy Cloughesy, MD, director of UCLA’s Neuro-Oncology Program and co-director of the UCLA Brain Tumor Center.
The study met its primary endpoint of increased immune-cell density. Whether the biological response translates into a consistent survival benefit remains a separate clinical question.
Survival Numbers Differ, but Proof of Benefit Remains Limited
Median overall survival was 402 days among patients assigned to groups receiving both checkpoint inhibitors, compared with 273 days for those assigned to nivolumab alone. UCLA also identified five long-term survivors in the combination-treatment groups.
The difference attracted attention because glioblastoma often progresses despite conventional treatment. However, the trial was designed primarily to measure immune activity, with survival evaluated as a secondary outcome.
Treatment schedules also differed between groups. Patients initially assigned to placebo received both drugs after surgery, while those receiving nivolumab alone continued that treatment. The survival analysis combined two groups that received dual therapy after surgery, even though their presurgical treatments differed.
That distinction matters when researchers document cancer treatment outcomes across different treatment schedules. A numerical difference in survival does not independently establish which component of a regimen contributed to the observed results.
Researchers also found that patients with greater T-cell density in their tumors tended to survive longer. Early changes in interferon-related genes detected in blood samples were similarly associated with outcomes.
These findings may help researchers identify biological indicators of treatment response, but neither measurement has been established as a reliable clinical test for selecting patients.
Some participants receiving both drugs also developed MRI changes consistent with pseudoprogression. This occurs when treatment-related inflammation resembles tumor enlargement on imaging. Researchers associated those changes with longer survival, although an apparent increase in tumor size cannot automatically be interpreted as a favorable treatment response.
The trial reported no unanticipated toxicities. Nevertheless, its findings do not eliminate the established risks associated with immune checkpoint inhibitors or determine whether the combination would produce similar results in a larger patient population.
Mouse Model Reproduces Glioblastoma’s Resistance to Immunotherapy
The second study, published in Cancer Research, addressed another challenge in glioblastoma research. Some laboratory models respond to immune checkpoint inhibitors more readily than human tumors, making it difficult to assess how experimental therapies might perform in patients.
Researchers from UCLA and Cedars-Sinai developed a genetically engineered mouse model using Mosaic Analysis with Dual-Recombinase, or MADR, alongside gene-editing methods.
The model incorporated EGFRvIII, a genetic alteration affecting the epidermal growth factor receptor pathway, together with the loss of tumor-suppressor genes PTEN and CDKN2A. These changes reflect molecular features observed in some human glioblastomas.
The resulting tumors spread through surrounding brain tissue and developed irregular borders and areas of tissue death. Their immune environments were dominated by myeloid cells, including microglia, with relatively few tumor-infiltrating T cells.
The tumors also resisted immune checkpoint blockade. In laboratory experiments, cancer cells showed resistance to targeted T-cell attacks and appeared to promote T-cell exhaustion, a state associated with reduced immune-cell function.
The findings suggest that glioblastoma resistance may involve multiple biological barriers, including limited T-cell presence and reduced effectiveness of immune cells that reach the tumor.
The mouse model and clinical trial produced complementary observations. In patients, higher tumor-infiltrating lymphocyte density was associated with longer survival. In the mouse model, limited T-cell infiltration accompanied resistance to checkpoint inhibitors.
Researchers also examined the relationship between EGFR alterations and treatment resistance. However, the observations do not establish that a particular genetic change can reliably predict an individual patient’s response.
The model provides a way to study treatment resistance under controlled experimental conditions. Its findings remain preclinical and do not establish the effectiveness of an additional therapy in humans.
Frequently Asked Questions
What did the UCLA brain cancer trial examine?
The UCLA brain cancer trial examined immune responses to nivolumab and ipilimumab in patients with recurrent glioblastoma. Researchers compared presurgical treatments and measured immune-cell density in tumor tissue removed during surgery.
Did the immunotherapy combination improve survival?
The study reported longer median survival among patients assigned to groups receiving both drugs. However, survival was a secondary outcome, and the trial did not establish a definitive survival benefit.
Why did researchers develop the mouse model?
The researchers sought to reproduce features of human glioblastoma that contribute to resistance against immune checkpoint inhibitors. The model allows scientists to investigate biological factors that may limit immune responses.
Can MRI scans or blood tests identify immunotherapy responders?
Certain MRI changes and blood-based immune signals were associated with longer survival in exploratory analyses. These findings have not established validated clinical tests for determining which patients will benefit from treatment.
Disclaimer:
This article is for informational and educational purposes only and does not constitute medical advice. The findings discussed do not establish that the treatments are safe or effective for all patients with glioblastoma. Individuals should consult qualified healthcare professionals regarding diagnosis, treatment options and medical decisions.
